13F HOLDINGS REPORT
Artia Global Partners LP
Quarter ended Q4 2023 · Filed November 14, 2023 · Accession 0001937964-23-000006
Total Value
$240.6M
Positions
27
Other Managers
0
Confidential Omitted
No
Holdings (27)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | NOVO-NORDISK A S | NONOF | 681,812 | $62.0M | 25.78% |
| 2 | MERCK & CO INC | MRK | 329,200 | $33.9M | 14.09% |
| 3 | ARGENX SE | ARGX | 49,238 | $24.2M | 10.06% |
| 4 | LILLY ELI & CO | LLY | 26,193 | $14.1M | 5.85% |
| 5 | ABBVIE INC | ABBV | 90,821 | $13.5M | 5.63% |
| 6 | ASTRAZENECA PLC | AZN | 190,752 | $12.9M | 5.37% |
| 7 | SEAGEN INC | SE | 51,175 | $10.9M | 4.51% |
| 8 | ROIVANT SCIENCES LTD | ROIV | 914,023 | $10.7M | 4.44% |
| 9 | 89BIO INC | 282559103 | 465,465 | $7.2M | 2.99% |
| 10 | BIOMARIN PHARMACEUTICAL INC | BMRN | 78,465 | $6.9M | 2.89% |
| 11 | SAREPTA THERAPEUTICS INC | SRPT | 57,162 | $6.9M | 2.88% |
| 12 | VERTEX PHARMACEUTICALS INC | VRTX | 18,314 | $6.4M | 2.65% |
| 13 | AXSOME THERAPEUTICS INC | AXSM | 87,848 | $6.1M | 2.55% |
| 14 | NEUROCRINE BIOSCIENCES INC | NBIX | 45,000 | $5.1M | 2.10% |
| 15 | VIKING THERAPEUTICS INC | VKTX | 383,580 | $4.2M | 1.77% |
| 16 | ALNYLAM PHARMACEUTICALS INC | ALNY | 15,971 | $2.8M | 1.18% |
| 17 | INTRA-CELLULAR THERAPIES INC | 46116X101 | 41,600 | $2.2M | 0.90% |
| 18 | VAXCYTE INC | PCVX | 38,555 | $2.0M | 0.82% |
| 19 | PROTAGONIST THERAPEUTICS INC | PTGX | 112,340 | $1.9M | 0.78% |
| 20 | PLIANT THERAPEUTICS INC | PLRX | 100,000 | $1.7M | 0.72% |
| 21 | CHARLES RIV LABS INTL INC | 159864107 | 6,905 | $1.4M | 0.56% |
| 22 | THERMO FISHER SCIENTIFIC INC | TMO | 2,109 | $1.1M | 0.44% |
| 23 | WATERS CORP | 941848103 | 2,845 | $780,127 | 0.32% |
| 24 | TYRA BIOSCIENCES INC | TYRA | 45,253 | $623,134 | 0.26% |
| 25 | CYMABAY THERAPEUTICS INC | 23257D103 | 41,261 | $615,202 | 0.26% |
| 26 | BIOMEA FUSION INC | BMEA | 25,452 | $350,220 | 0.15% |
| 27 | GRITSTONE BIO INC | 39868T105 | 95,170 | $163,692 | 0.07% |